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Abstract The anti-ICAM-1 monoclonal antibody FI0.2 was 
conjugated to liposomes to target to cells expressing the cell 
adhesion molecule ICAM-1. We demonstrate that F10.2 immu- 
noliposomes bind to human bronchial epithelial cells (BEAS-2B) 
and human umbilical vein endothelial cells (HUVEC) in a spe- 
cific, dose- and time-dependent manner. It appears that the de- 
gree of ICAM-I expression is the limiting factor in the degree 
of immunoliposome binding to the cells. These results are a first 
step in the strategy for specific drug delivery to target sites 
characterised by increased expression of adhesion molecules. 
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1. Introduction 
Cell adhesion molecules are (glyco)proteins which are ex- 
pressed on the cell membrane and are involved in homotypic 
and heterotypic cell interactions. Since cell-cell interactions are 
crucial in pathophysiological events, adhesion molecules play 
an important role in processes like wound healing, tumor me- 
tastasis formation, lymphocyte homing, and lymphocyte and 
granulocyte extravasation [1-5]. Evidence is accumulating that 
the expression of particular cell adhesion molecules, such as 
intercellular adhesion molecule-1 (ICAM-1), E-selectin, P-se- 
lectin and/or vascular cell adhesion molecule-1 (VCAM-1), is 
locally induced or enhanced at areas of inflammation [6]. These 
adhesion molecules mediate the invasion of leukocytes into 
extravascular tissue at pathological sites of e.g. rheumatoid 
arthritis [7,8], atopic dermatitis [9], inflammatory bowel dis- 
eases [10], and asthma [11,12]. Induction and/or increased ex- 
pression of certain cell adhesion molecules at inflammatory loci 
associated with various diseases offers opportunities for the 
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development of new therapeutic strategies. Monoclonal anti- 
bodies (mAbs) against adhesion molecules have been used to 
inhibit leukocyte recruitment into areas of dermal, synovial and 
lung inflammation [13 16], to increase survival in animal mod- 
els of septic shock [17], and to prevent ameliorate tissue damage 
caused by ischemia-reperfusion njury [18]. Another opportu- 
nity for therapeutic intervention is to couple these mAbs to 
liposomes (immunoliposomes) for the purpose of drug target- 
ing. This study deals with the use of an anti-ICAM-1 mAb to 
direct liposomes to target cells expressing the adhesion mole- 
cule ICAM-1. This is a first step in the strategy for specific 
delivery of bioactive substances to target sites characterized by 
increased expression of adhesion molecules. 
Liposomes conjugated with mAbs (referred to as immu- 
noliposomes) offer several advantages over direct mAb-drug 
conjugates [19]. First, large quantities of a wide range of polar 
and lipophilic drugs can be encapsulated in liposomes, while 
usually not more than a few drug molecules can be directly 
coupled to soluble dru~antibody conjugates. Therefore, the 
relatively large pay-load per immunoliposome permits the 
transfer of large numbers of drug molecules to an individual 
target site. Secondly, encapsulation does not require linking of 
the drug to the targeting ligand via chemical bonds, which must 
be degraded before drug activity can be displayed. Moreover, 
the immunoliposome particle protects the drug from metabolic 
degradation until it reaches its destination. Finally, many mAbs 
of a single or multiple different specificities can be bound to the 
surface of a single liposome. Such immunoliposomes can bind 
to cells expressing the target antigen by multivalent interactions 
[20,211. 
Immunoliposomes specifically directed against he adhesion 
molecule ICAM-1 were prepared, using the anti-ICAM-I mAb 
F 10.2 [22], characterised and evaluated for their in vitro binding 
capacity to cells expressing ICAM-1. As target cells we used 
human umbilical vein endothelial cells (HUVEC) and the bron- 
chial epithelial cell line BEAS-2B, which are well characterized 
for their ICAM-1 expression [23,24]. We show that the F10.2- 
mediated targeting of liposomes to ICAM-1 expressing cells is 
rapid, specific and positively correlated with the degree of 
ICAM-1 expression. The use of antibodies to target liposomes 
to cell adhesion molecules has not been reported previously. 
2. Materials and methods 
2.1. Materials" 
2.1.1. Materials" for liposome preparation. Partially hydrogenated 
egg-phosphatidyl choline with an iodine value of 40 (PHEPC; Asahi 
Chemical Industry Co., Ibarakiken, Japan) was prepared as described 
previously [25]. Egg-phosphatidylglycerol (EPG) was a gift from 
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Nattermann GmbH (Cologne, Germany). Rhodamine-PE was ob- 
tained from Lipid Products (South Nutfield, UK), N-succinimidyl-S- 
acetylthioacetate (SATA) from Pierce Chemical Co. (Rockford, IL, 
USA), cholesterol (CHOL) and N-ethylmaleimide from Sigma Chemi- 
cal Co. (St Louis, MO, USA), and dimethylformamide (DMF) and 
hydroxylamine from Janssen (Beerse, Belgium). 
2.1.2. Sources for mediators and mAbs. Tumor necrosis factor-~ 
(TNF-~; Genzyme Corp., Cambridge, MA, USA); interferon-y (IFN- 
7/; Boehringer-Mannheim G bH, Mannheim, Germany); keratinocyte 
medium (Keratinocyte-SFM; Gibco, Grand Island, NY, USA); RPMI 
1640 (Gibco); vitrogen (Celtrix Laboratories, Palo Alto, CA, USA), 
fibronectin (Centraal Laboratorium Bloedtransfusiedienst (CLB), Am- 
sterdam, The Netherlands); heat-inactivated pooled human serum 
(CLB); bovine serum albumin (BSA; fraction V) with less than 0.1 
ng/mg endotoxin (Sigma); FITC-labeled goat anti-mouse mAb 
(GamFITC; Becton-Dickinson Monoclonal Center, Mountain View, 
CA, USA) and anti-ICAM-1 mAb (IgG0, clone F10.2 [22]. The mAbs 
anti-ICAM-1 (IgG2a), clone R6.5 and anti-CD18 (IgG1), clone R15.7 
were kindly donated by Dr. C.D. Wegner (Department of Pharmacol- 
ogy, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA). All 
other reagents were of the highest grade available. 
2.2. Cell cultures 
The human bronchial epithelial cell line BEAS-2B [26] was obtained 
from Dr. J.F. Lechner (National Institute of Health, Bethesda, MD, 
USA) and cultured as described by Bloemen et al. [23]. Briefly, BEAS- 
2B cells were cultured in a serum-free keratinocyte medium with 50/lg/ 
ml gentamycin on a coat of vitrogen, fibronectin and BSA. The cell line 
was not used after passage 30. 
Human umbilical cord vein endothelial cells (HUVEC; kind gift of 
Dr. J. de Vlieger, Department of Pharmacology, Utrecht Institute for 
Pharmaceutical Sciences, Utrecht University, The Netherlands) were 
isolated from human umbilical cord vein and cultured in fibronectin 
coated plastic culture flasks (Costar, Cambridge, MA, USA) using 
RPMI 1640 supplemented with 20% heat-inactivated pooled human 
serum, penicillin (100 U/ml) and streptomycin (100 pg/ml). 
The murine CT4S cell line (kindly donated by Dr. W.P. Paul, Na- 
tional Institute of Health, Bethesda, MD, USA) was cultured in RPMI 
1640 with 10% foetal calf serum (FCS). 
The cell lines were free of mycoplasma contamination a d cultured 
at 37°C with 5% CO: in humidified air. 
2.3. Preparation of thiolated mAb 
The F10.2 mAb was eluted from a gel-filtration column (Sephadex 
G-25M, PD-10) with HEPES buffer (10 mM HEPES, 135 mM NaC1, 
1 mM EDTA) and subsequently concentrated (10 kDa Microsep; Fil- 
tron Technology Corp., Northborough, MA, USA) to a standard con- 
centration of about 1 mg protein/ml. Thiol groups were introduced at 
the site of primary amino groups in the molecule by using the SATA 
reaction proposed by Duncan and co-workers [27]. SATA was dis- 
solved in DMF at a concentration f 5 mM. The solutions were mixed 
in a volume ratio of SATA/F10.2 mAb = 1/100. They were incubated 
at room temperature for 20 min at pH 7.4 under constant rotation with 
a SATA/F10.2 mAb molar ratio of 8:1. Immediately after incubation, 
acetylthioacetyl-protein (protein-ATA) was separated from unreacted 
reagent by gel-filtration on a Sephadex G-25M column (PD-10). The 
protein fractions in the eluate were detected by monitoring the absorp- 
tion at 280 nm. The F10.2 mAb containing fractions were combined 
and stored at -20°C. Before coupling to MPB-PE liposomes (see 
below), protein-ATA was deacetylated byadding a freshly prepared 0.5 
M hydroxylamine-HC1 solution containing 0.5 M HEPES, 25 mM 
EDTA (pH 7.5) at a volume ratio of protein-ATA solution/NH:OH 
solution = 10/1; the incubation lasted 1 h. 
2.4. Preparation of immunoliposomes 
Immunoliposomes were prepared by conjugating the anti-ICAM-1 
mAb F10.2 to preformed liposomes containing the anchor molecule 
MPB-PE. N-[4-(p-Maleimidophenyl) butyryl]phosphatidylethanolamine 
(MPB-PE) was synthesized, purified and analyzed as described before 
[28,29]. MPB-PE was incorporated into the liposomal bilayers to allow 
covalent coupling of thiol containing proteins to the liposomal surface 
[30-33]. The lipid composition of the liposomes used was PHEPC/EPG/ 
CHOL/MPB-PE/rhodamine-PE at a molar ratio of 10/1/4/0.4/0.01. A 
mixture of the appropriate amounts of lipids in chloroform/methanol 
(10/1, v/v) was evaporated to dryness by rotary evaporation at 35°C 
under educed pressure. After flushing with nitrogen, the lipid film was 
hydrated in HEPES buffer. The resulting liposome dispersion was se- 
quentially extruded through polycarbonate membrane filters of 0.6 and 
0.2/tm pore size (Unipore, Bio-Rad, Richmond CA, USA) under nitro- 
gen pressure up to 0.8 MPa. The freshly prepared liposomes were mixed 
with freshly deacylated, thiolated F10.2 mAb (concentrations during 
incubation amounted to about 10/lmol phospholipid (PL)/ml and 0.25 
mg mAb/ml, respectively). The coupling reaction was allowed to take 
place for 75 min at room temperature under constant rotation in nitro- 
gen atmosphere. The coupling reaction was stopped by adding 50 pl of 
N-ethylmaleimide (8 mM in HEPES buffer). Finally, the immu- 
noliposomes were separated from unconjugated antibody by ultracen- 
trifugal sedimentation at 100,000 x g for 30 min at 4°C. The pellet was 
resuspended and washed three times with HEPES buffer. MPB-PE- 
containing liposomes not incubated with thiolated mAb are referred to 
as 'MPB-PE liposomes'. Liposomes without incorporated MPB-PE are 
referred to as 'liposomes'. Liposome dispersions were stored at 4°C. 
2.5. Liposome characterisation 
Lipid phosphate was determined by the colorimetric method of Fiske 
and Subbarow [34]. The amount of protein coupled to the liposomes 
was determined by the method of Wessel and Flfigge [35], with BSA as 
standard. The amount of mAb coupled to the liposomes was expressed 
as/.tg protein/pmol PL. The protein coupling ratios of the F 10.2 immu- 
noliposomes varied between 4 and 8 pg protein/pmol PL. Mean particle 
size was determined by dynamic light scattering with a Malvern 4700 
system using a 25 mW helium-neon laser and the AUTOMEASURE 
vsn. 3.2 software (Malvern Ltd., Malvern, UK). For viscosity and 
refractive index the values of pure water were used. As a measure of 
the particle size distribution of the dispersion the system reports a 
polydispersity index. This index ranges from 0.0 for an entirely mono- 
disperse up to 1.0 for a completely polydisperse dispersion. The li- 
posomes had a mean size of 0.25~3.30 pm and a polydispersity index 
varying between 0.1 and 0.3. It can be estimated that 40 80 mAb 
molecules were coupled to one liposome particle. 
2.6. Analysis of lCAM-1 expression 
Confluent monolayers of BEAS-2B cells and HUVEC (non-stimu- 
lated or stimulated for 24 h by pretreatment with IFN-~' (200 U/ml) and 
TNF-c~ (20 ng/ml), respectively) were detached using HEPES-buffered 
saline (HBS), EDTA (0.02%) for 10-15 min. CT4S cells were detached 
by use of a cell scraper. The different cell types were subsequently 
washed with phosphate buffered saline (PBS), 0.1% BSA, 0.05% sodium 
azide. Aliquots of 5 x 105 cells were incubated with the anti-ICAM-1 
mAb F10.2 at a concentration f 25/.tg/ml (incubation volume 50 pl) 
for 30 min on ice. Subsequently, they were incubated for another 30 min 
with a FITC-conjugated goat anti-mouse IgG (GamFITC). Finally, the 
cells were washed 3 times and analyzed by flowcytometry under identi- 
cal settings for all cell types (FACScan, Becton-Dickinson). The 
ICAM-1 expression isexpressed as fluorescence intensity (x-axis) plot- 
ted on a log scale vs. cell number (y-axis). The mean fluorescence 
intensity (MFI) was calculated from these histograms and used in the 
figures. The MFI of the negative control (GamFITC labeling only) was 
<-3 for BEAS-2B cells and <- 12 for HUVEC. 
2. 7. Liposome binding assay 
Detached BEAS-2B cells (see section 2.6.) were washed in Ker- 
atinocyte-SFM medium and detached HUVEC and CT4S cells in 
RPMI 1640. Resuspended cells (5 x l0 s) were incubated with varying 
lipid concentrations of liposomes, MBP-PE liposomes or F10.2 immu- 
noliposomes in a total volume of 200 pl for 0-4 h at 37°C. The cell/ 
liposome suspensions were washed twice with PBS, 0.1% BSA, 0.05% 
sodium azide to remove unbound liposomes before analysis on the 
flowcytometer on identical settings as mentioned before. Intensity of 
liposome binding as monitored by the presence of rhodamine-PE 
(2ex c= 560 nm, ~'~m = 590 nm) in the liposome was expressed as fluores- 
cence intensity (x-axis) plotted on a log scale histogram vs. cell number 
(y-axis). The MFI were calculated from these histograms and used in 
the figures. In the liposome binding inhibition experiments, 5 x 105 
epithelial cells or HUVEC were preincubated with different mAbs 
(F10.2, R6.5, or R15.7) at a concentration of 25 /tg/ml (incubation 
volume 50/11) for 30 rain on ice. Subsequently, the cells were washed 
and incubated with the liposome suspension for 1 h at 37°C. 
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Fig. 1. ICAM-1 expression (A,C) and F10.2 immunoliposome binding (B,D) to BEAS-2B cells and HUVEC. The cells were detached after 24 h of 
incubation without cytokines (thin lines) or with IFN-y for BEAS-2B cells and TNF-~ for HUVEC (dark lines). 5 × 105 cells (A,C) were incubated 
with the anti-ICAM-1 mAb F10.2 (at a concentration f 25 pg/ml) and subsequently wih GamFITC. In parallel, BEAS-2B cells and HUVEC were 
incubated with F10.2 immunoliposomes at a concentration f 6 pmol PL/ml for 1 h at 37°C (B,D). Representative examples of ICAM-1 expression 
(A,C) and liposome binding (B,D) as measured by flowcytometry are shown. Binding of the control iposomes; i.e. 'liposomes' and MBP-PE liposomes 
gave a MFI -< 7 on BEAS-2B cells and a MFI -< 19 on HUVEC, independent of the activation state of the cell. 
3. Results and discussion 
As specific association of immunol iposomes with their target 
cells is a necessary requirement for target-specific drug delivery, 
the binding of F10.2 immunoliposomes, containing rhodamine- 
PE as fluorescent bilayer marker, to BEAS-2B cells and 
HUVEC was evaluated. Both cell types expressed ICAM-1 on 
their surface under normal culture conditions (Fig. 1A,C; 
MF I  = 152 for BEAS-2B cell and MF I  = 57 for HUVEC).  
ICAM- I  expression on BEAS-2B cells was increased 2-fold 
(MFI  = 302) and on HUVEC 13-fold (MFI  = 723) after incu- 
bat ion for 24 h with IFN-7  and TNF-ct, respectively (Fig. 
1A,C). Binding of the F10.2 immunol iposomes to the cells was 
monitored by flowcytometry after 1 h of incubation at 37°C. 
The F10.2 immunol iposomes appeared to bind to both BEAS- 
2B cells and HUVEC under non-stimulated conditions 
(MFI  = 30 and 13, respectively). The amount  of l iposomes 
bound was clearly increased on BEAS-2B cells (MFI  = 62) and 
on HUVEC (MFI  = 117) after up-regulation of the surface 
expression of ICAM-1 by the respective cytokine pretreatment 
(Fig. 1B,D). 
Fig. 2 shows the effect of the incubation time on the degree 
Table 1 
Inhibition of F10.2 immunoliposome c ll binding by preincubation of BEAS-2B and HUVEC with soluble anti-ICAM-1 mAbs 
No pre-incubation Pre-incubation with F10.2 Pre-incubation with R6.5 Pre-incubation with R15.7 
(MFI) (MFI) (MFI) (MFI) 
Experiment I II III I II III I II I I1 
BEAS-2B (NS) 16 14 12 9 7 4 9 7 16 18 
BEAS-2B (IFN-y) 39 31 37 17 8 16 16 12 42 25 
HUVEC (NS) 13 16 ND 14 9 ND ND ND ND ND 
HUVEC (TNF<z) 117 48 ND 33 14 ND ND ND ND ND 
BEAS-2B cells and HUVEC were respectively incubated with or without IFN-y or TNF-~ for 24 h. After detachment, aliquots of 5x 105 cells were 
incubated with control medium, R15.7 (anti-CD18), R6.5 or FI0.2 (anti-ICAM-1) for 30 min on ice. After washing, these cells were subsequently 
incubated with F10.2 immunoliposomes at a concentration f 6 ,umol PL/ml for 1 h at 37°C. Liposome binding was analyzed with a flowcytometer 
and expressed as MFI. Experiment I, II and III represent the data of experiments performed with seperate immunoliposome formulations. NS, not 
stimulated; ND, not done. 
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Fig. 2. Time-course of liposome binding to BEAS-2B cells. 5 × 105 
non-stimulated (circles) or IFN-~, stimulated (triangles) cells were incu- 
bated at 37°C with F10.2 immunoliposomes at a concentration of 
1.2/.tmol PL/ml. These experiments were carried out with 2 different 
liposome preparations. Results of a typical experiment are shown. 
of liposome binding to BEAS-2B cells. Under the chosen condi- 
tions, cell binding to non-stimulated and IFN-7 stimulated cells 
was nearly maximal after 1 h of incubation, demonstrating that 
an incubation period of 1 h was sufficient. The time-curve was 
similar for the different liposome preparations studied and 
therefore independent of the coupling ratio. 
Fig. 3 shows that the number of cell-bound immu- 
noliposomes increased with the liposomal lipid concentration 
in the incubation mixture. Clearly, the degree of liposome bind- 
ing to the cells was increased after incubation of the BEAS-2B 
cells with IFN-y at all lipid concentrations tested. Similar con- 
centration curves were found with the different liposome prep- 
arations. 
To show the specificity of the F10.2 immunoliposome bind- 
ing towards ICAM-1 expressing cells, negative control binding 
experiments were performed using MPB-PE liposomes and li- 
posomes without incorporated MPB-PE ('liposomes'). These 
negative control incubations resulted in very low binding values 
75 
A 
SO 
MFI 
even at high lipid concentrations (Fig. 3). In addition, F10.2 
immunoliposomes did not bind to murine CT4S cells which do 
not express ICAM-1 recognised by F10.2, as confirmed by 
flowcytometry (MFI = 2 for ICAM-I expression and MFI -- 4 
for liposome binding). In line with these results, F10.2 immu- 
noliposome binding to neutrophils, monocytes or lymphocytes 
was not detectable, which corresponds with the low ICAM-1 
expression on leukocytes in comparison with the endothelial 
and epithelial cells used (data not shown). To further demon- 
strate the specific nature of the immunoliposome-cell interac- 
tion, experiments were designed to study whether this interac- 
tion could be blocked by preincubation of the target cells with 
soluble mAb directed against ICAM-1. Although directed 
against different epitopes on ICAM-1 [22,36,37], the mAbs 
FI0.2 and R6.5 both inhibited the binding of F10.2 immu- 
noliposomes to non-stimulated and stimulated BEAS-2B cells 
(Table 1). Steric hindrance might be an explanation for the 
inhibition of F 10.2 immunoliposome binding by the mAb R6.5. 
Preincubation of the cells with an irrelevant isotype matched 
mAb R15.7 (anti-CD18) had no inhibitory effect (Table 1). 
Identical experiments with HUVEC yielded similar results 
(Table 1). 
The relationship between the degree of ICAM-1 expression 
on the different cell types and the amount of liposomes bound 
to these cells is shown in Fig. 4. Linear regression analysis 
revealed a highly significant positive correlation (r = 0.975, 
P < 0.001 for experiment I, and r = 0.956, P < 0.05 for experi- 
ment II). It appears that the degree of ICAM-1 expression is 
the limiting factor in the degree of liposome binding to the cells. 
In addition, it is also clear from Fig. 4 that the degree of F10.2 
immunoliposome binding is dependent on the number of mAb 
molecules present on the surface of the liposomes. Together, 
these results (Figs. 3, 4, and Table 1) indicate that F10.2 immu- 
noliposomes bind specifically to cells expressing ICAM-1. 
It should be realised that the present experimental design to 
monitor cell binding of liposomes does not discriminate be- 
tween liposome binding to the cell surface and uptake into the 
cell. The subsequent events which follow liposome cell binding 
via the ICAM-l /mAb interaction are currently under investiga- 
tion. Since the fate of the liposome largely dictates the routing, 
and therefore action, of an encapsulated drug, the nature of 
these events have to be elucidated. 
In conclusion, we have demonstrated for the first time the 
75,50 
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Fig. 3. Effect of lipid concentration the degree of liposome binding to BEAS-2B cells. 5 x 105 (IFN-y stimulated (B) or non-stimulated (A)) cells 
were incubated with 'liposomes' (squares), MPB-PE liposomes (circles) or F10.2 immunoliposomes (triangles) for 1 h at 37°C (n = 3). These 
experiments were carried out with 3 different liposome preparations. Results of a typical experiment are shown. 
144 P G M. Bloemen et al./FEBS Letters 357 (1995) 14~144 
120 ! 
Uposome E r =0,995 
binding 
(MFI)  lOO 
80 
60 D 
l I  
40 C E r =0.956 
oD 
20 
A 
0 
o 2~o 4~o ~o 8~o 
ICAM-1 express ion (MFI)  
Fig. 4. Effect of degree of ICAM-1 expression on the degree of cell 
binding of F10.2 immunoliposomes. The degree of ICAM-1 expression 
and the degree of cell binding of F10.2 immunoliposomes were deter- 
mined for different cell populations and two immunoliposome formula- 
tions differing in coupling ratio (7.7 ~g protein/pmol PL for experiment 
I and 4.2/tg protein/,umol PL for experiment II). The following cells 
were used: A, CT4S; B, HUVEC (non-stimulated); C, BEAS-2B (non- 
stimulated); D, BEAS-2B (IFN-y) and E, HUVEC (TNF-c 0. 5 × 105 
cells (BEAS-2B, HUVEC, and CT4S) were incubated with F10.2 immu- 
noliposomes ata PL concentration f 6/tmol PL/ml for 1 h at 37°C. 
ICAM-1 expression expressed as MFI (x-axis) is plotted against F10.2 
immunoliposome binding to the different cells expressed as MFI 
(y-axis) (r = 0.975, P -< 0.001 for experiment I, and r = 0.956, P < 0.05 
for experiment II). 
potential usefulness of immunoliposomes for targeted rug de- 
livery to cells expressing adhesion molecules. Immu- 
noliposomes specifically directed against cells expressing 
ICAM- 1 were prepared, characterized and shown to be capable 
of binding specifically to target cells from different origins in 
vitro. Moreover, the results presented in this study open up a 
new avenue in drug delivery research; i.e immunoliposomes 
containing drugs can be targeted to a pathological site charac- 
terized by an increased expression of certain adhesion mole- 
cules and act as a localized drug depot. Further studies will 
address the many remaining issues such as extent of cellular 
internalization f cell-bound immunoliposomes, the quantifica- 
tion of the degree of liposome binding to the cell, the general 
applicability of this approach for targeting to other types of cell 
adhesion molecules (such as E-selectin, P-selectin or VCAM-I 
[1,9,38]) only expressed at the site of an inflammatory process 
and totally absent on blood leukocytes, and the validation of 
the concept in suitable in vivo models. 
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